Cargando…

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells

The use of antibodies in therapy and diagnosis has undergone an unprecedented expansion during the past two decades. This is due in part to innovations in antibody engineering that now offer opportunities for the production of “second generation” antibodies with multiple specificities or altered val...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Jeffrey C, Poovassery, Jayakumar S, Bansal, Pankaj, You, Sungyong, Manjarres, Isabel M, Ober, Raimund J, Ward, E Sally
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984324/ https://www.ncbi.nlm.nih.gov/pubmed/24492289 http://dx.doi.org/10.4161/mabs.27658

Ejemplares similares

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
por: Kang, Jeffrey C., et al.
Publicado: (2019)

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells
por: Ram, Sripad, et al.
Publicado: (2014)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2004)

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
por: Buta, Corina, et al.
Publicado: (2016)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Microscope calibration protocol for single-molecule microscopy
por: You, Sungyong, et al.
Publicado: (2020)

Engineered clearing agents for the selective depletion of antigen-specific antibodies
por: Devanaboyina, Siva Charan, et al.
Publicado: (2017)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET
por: Khare, Priyanka, et al.
Publicado: (2021)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
por: Al-Akhrass, Hussein, et al.
Publicado: (2021)

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
por: Momeny, Majid, et al.
Publicado: (2015)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

γ-Heregulin has no biological significance in primary breast cancer
por: Sánchez-Valdivieso, E A, et al.
Publicado: (2002)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells
por: Kim, Sangmin, et al.
Publicado: (2012)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Heregulin, a new regulator of telomere length in human cells
por: Menendez, Javier A., et al.
Publicado: (2015)

Heregulin Activity Assays for Residual Testing of Cell Therapy Products
por: Monje, Paula V., et al.
Publicado: (2021)

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

Phagocytosis of antibody‐opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages
por: Velmurugan, Ramraj, et al.
Publicado: (2018)

Correction: High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck
por: Shames, David S., et al.
Publicado: (2013)

Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
por: Mitsui, Keigo, et al.
Publicado: (2014)

Heregulin, a new interactor of the telosome/shelterin complex in human telomeres
por: Menendez, Javier A., et al.
Publicado: (2015)

Commentary: “There’s been a Flaw in Our Thinking”
por: Ward, E. Sally, et al.
Publicado: (2015)

Model-driven engineering of supramolecular buffering by multivalency
por: Paffen, Tim F. E., et al.
Publicado: (2017)

Androgen receptor transcriptional activity is required for heregulin-1β–mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase
por: Jathal, Maitreyee K., et al.
Publicado: (2023)

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer
por: Steele, Thomas M., et al.
Publicado: (2023)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease
por: Sun, Wei, et al.
Publicado: (2021)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Suppression of Heregulin-β1/HER2-Modulated Invasive and Aggressive Phenotype of Breast Carcinoma by Pterostilbene via Inhibition of Matrix Metalloproteinase-9, p38 Kinase Cascade and Akt Activation
por: Pan, Min-Hsiung, et al.
Publicado: (2011)

Orthogonal dual-modification of proteins for the engineering of multivalent protein scaffolds
por: Mühlberg, Michaela, et al.
Publicado: (2015)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands
por: Wakefield, Devin L., et al.
Publicado: (2023)

Ultrahigh accuracy imaging modality for super-localization microscopy
por: Chao, Jerry, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1sthnntvatskklg1ope0qtt0g6